abaloparatide

Trade name: tymlos

Peptideapproved

Approved

Apr 28, 2017

Abaloparatide (brand name Tymlos) is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Abaloparatide is a PTHrP(1-34) analog which acts as an agonist at the PTH1 receptor (PTH1R). This results in activation of the cAMP signaling pathway in target cells. In rats and monkeys, abaloparatide had an anabolic effect on bone, demonstrated by increases in BMD and bone mineral content (BMC) that correlated with increases in bone strength at vertebral and/or nonvertebral sites. Abaloparatide was approved in April 28, 2017 by the FDA (as Tymlos) for the treatment of postmenopausal women with osteoporosis at high risk for fracture. — NCATS

Clinical trial activity

17 trials · 14 clinical orgs · 2 marketing orgs

Phase 1
4
Phase 2
10
Phase 3
4
Phase 4
3

Earliest trial started Apr 1, 2007 (NCT00542425)

Timeline

2000s

  1. Dec 9, 2005

    Ipsen — IND Organization

  2. Dec 9, 2005

    Ipsen — IND Organization

  3. Jan 1, 2007

    Radius Health — Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Radius Health — Earliest Phase 3 Sponsor(trial)

  2. Apr 28, 2017

    Radius Health — Earliest FDA Approval

  3. Apr 28, 2017

    Radius Health — NDA Organization

  4. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Mechanism of action

Approval history

  • approvedApr 28, 2017

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only
Multi-specific
No

Oral

No

Parenteral

Yes

Topical

No

Black box warning

Sources

Also known as

  • abaloparatide
  • abaloparatide
  • abaloparatide
  • abaloparatide
  • abaloparatide
  • abaloparatide
  • ba058
  • ba058
  • ba058
  • ba-058
  • bim-44058
  • tymlos

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04760782Phase 2Feb 28, 2021University of Vermont
NCT04626141Phase 4Jan 31, 2021Geisinger Clinic, Radius Health
NCT04663464Phase 1Nov 16, 2020Medpace, Inc., Radius Health
NCT04936984Phase 1Nov 16, 2020Medpace, Inc., Radius Health
NCT04467983Phase 4Aug 1, 2020Crozer Chester Medical Center, Pennsylvania, Osteoporosis Center of Delaware County, Radius Health
NCT04249232Phase 2Mar 31, 2020Cornell University, Lenox Hill Hospital, New York Hospital Queens, Rockefeller University
NCT04167163Phase 4Dec 31, 2019University of Wisconsin
NCT04064411Phase 3Aug 5, 2019Radius Health
NCT03708926Phase 2Jun 30, 2019Johns Hopkins University
NCT03841058Phase 2May 31, 2019Rockefeller University
NCT04366726Phase 1Apr 9, 2019Radius Health
NCT03746041Phase 1Feb 14, 2019University of Rochester
NCT03710889Phase 3Sep 20, 2018Radius Health
NCT03512262Phase 3Mar 30, 2018Radius Health
NCT01674621Phase 2Aug 1, 2012Nordic Bioscience, Radius Health
NCT01343004Phase 3Apr 1, 2011Radius Health
NCT00542425Phase 2Apr 1, 2007Radius Health
Showing 17 of 17 trials
Page 1 / 1

Organizations

Research & Development (14)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Radius HealthFor profit11942007
Medpace, Inc.For profit2012020
Rockefeller UniversityAcademic/Hospital2212019
Cornell UniversityAcademic/Hospital1012020
Crozer Chester Medical Center, PennsylvaniaAcademic/Hospital1012020
Geisinger ClinicAcademic/Hospital1112021
Johns Hopkins UniversityAcademic/Hospital1112019
Lenox Hill HospitalAcademic/Hospital1012020
New York Hospital QueensAcademic/Hospital1012020
Nordic BioscienceFor profit1012012
Osteoporosis Center of Delaware CountyAcademic/Hospital1112020
University of RochesterAcademic/Hospital1112019
University of VermontAcademic/Hospital1112021
University of WisconsinAcademic/Hospital1112019
14 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
IpsenFor profitINDDec 9, 2005
Radius HealthFor profitNDAApr 28, 2017